Shattuck Labs, Inc. (STTK)
$
3.1
+0.13 (4.19%)
Key metrics
Financial statements
Free cash flow per share
-0.6765
Market cap
100.6 Million
Price to sales ratio
2.8986
Debt to equity
0.0188
Current ratio
17.0019
Income quality
0.8883
Average inventory
0
ROE
-0.7382
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Shattuck Labs, Inc. is a clinical-stage biotechnology company that focuses on developing therapeutics for cancer and autoimmune diseases in the United States. The gross profit ratio is 1.00 reflecting the efficiency of the company's production and sales operations. The cost of revenue for the company is $0.00 showcasing its production and operational expenses. The financial data pertains to the fiscal year 2024 providing a clear picture of its economic performance. The company incurred an interest expense of $0.00 reflecting its debt servicing obligations. Additionally, the total costs and expenses for the company are $86,288,000.00 reflecting its overall spending. Shattuck Labs' lead product candidate, SL-172154, is currently undergoing a Phase 1 clinical trial aimed at treating ovarian, fallopian tube, and peritoneal cancers, while another candidate, SL-279252, is also in a Phase 1 trial for advanced solid tumors and lymphoma. Established in 2016, Shattuck Labs is headquartered in Austin, Texas. With a market capitalization of $148,499,967.00 the company is classified as a small-cap player, making it an interesting opportunity for investors. The stock is affordable at $2.28 suitable for budget-conscious investors looking for entry points in the market. The stock has an average trading volume of 358,547.00 indicating moderate liquidity, which can appeal to those interested in active trading. As a key player in the Biotechnology industry, Shattuck Labs contributes significantly to the overall market landscape, driving innovation and growth in the field of biotechnology. It belongs to the Healthcare sector, where advancements are critical for addressing unmet medical needs and improving patient outcomes.
Is Shattuck Labs, Inc. (STTK) a good investment?
Investing in Shattuck Labs, Inc. (STTK) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Shattuck Labs, Inc. (STTK)'s stock forecast?
Analysts predict Shattuck Labs, Inc. stock to fluctuate between $0.69 (low) and $3.12 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Shattuck Labs, Inc.'s market capitalization?
As of 2025-12-05, Shattuck Labs, Inc.'s market cap is $148,499,967, based on 47,903,215 outstanding shares.
How does Shattuck Labs, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Shattuck Labs, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Shattuck Labs, Inc. (STTK) stock?
To buy Shattuck Labs, Inc. (STTK) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for STTK. Place an order (Market, Limit, etc.).
What is the best time to invest in Shattuck Labs, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Shattuck Labs, Inc. perform in the last earnings report?
Revenue: $5,721,000 | EPS: -$1.49 | Growth: -27.32%.
Where can I find Shattuck Labs, Inc.'s investor relations reports?
Visit https://www.shattucklabs.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Shattuck Labs, Inc.?
You can explore historical data from here
What is the all-time high and low for Shattuck Labs, Inc. stock?
All-time high: $22.62 (2021-09-09) | All-time low: $0.69 (2025-04-07).
What are the key trends affecting Shattuck Labs, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
benzinga.com
HC Wainwright upgraded Shattuck Labs Inc. (NASDAQ: STTK) from Neutral to Buy, with a price forecast of $6. The company's lead product candidate, SL-325, is a DR3 antagonist antibody for inflammatory bowel disease (IBD).
globenewswire.com
–First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers – – Closed a private placement of up to $103 million in August 2025 to support advancement of SL-325 – – Appointments of Dan Baker, M.D., and Mona Ashiya, Ph.D.
seekingalpha.com
Shattuck Labs, Inc. (NASDAQ:STTK ) The United European Gastroenterology (UEG) Congress UEG Week 2025 October 8, 2025 10:00 AM EDT Company Participants Taylor Schreiber - Co-Founder, CEO & Director Conference Call Participants Yu Fan - Wedbush Securities Inc., Research Division Marla C Dubinsky David De Vries - TR1X, Inc. David Nierengarten - Wedbush Securities Inc., Research Division Conversation Yu Fan Wedbush Securities Inc., Research Division Okay. Good morning, everybody.
zacks.com
Does Shattuck Labs, Inc. (STTK) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com
Shattuck Labs, Inc. (STTK) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, STTK's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
zacks.com
Shattuck Labs (STTK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
globenewswire.com
— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease —
globenewswire.com
– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 –
globenewswire.com
– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease –
globenewswire.com
AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present at and participate in one-on-one meetings at the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 2025.
See all news
